Table 1 FDA-approved drugs for neuroblastoma
Drug name (brand name) | Drug type (PubChem CID) | Cancer treatment | Mechanism of action | Route of administration |
|---|---|---|---|---|
Cyclophosphamide (Cytoxan, Procytox) | Small molecule (2907) | Neuroblastoma, ALL, AMoL, AML, CLL, CML, breast cancer, HL, MM, MF, neuroblastoma, NHL, ovarian cancer, retinoblastoma | Precursor of alkylating agents of metabolite PM, leading to DNA cross-linking and cell apoptosis | Oral or intravenous |
Dinutuximab (Unituxin) | Monoclonal antibody | Neuroblastoma | Binds to GD2 on the surface of cancer cells, triggering an immune response | Intravenous |
Doxorubicin hydrochloride (Adriamycin, Doxil, Caelyx, Rubex, Myocet) | Small molecule (443939) | Neuroblastoma, ALL, AML, breast cancer, gastric cancer, HL, NHL, NSCLC, soft tissue and bone sarcomas, thyroid cancer, transitional cell bladder cancer, Wilms tumor | Interacting with DNA interferes with Topo II activity and prevents relegation of Topo-mediated DNA breaks, leading to inhibition of replication and transcription and induction of apoptosis. | Intravenous |
Eflornithine hydrochloride or DFMO (Iwilfin, Vaniqa) | Small molecule (57004) | Neuroblastoma | Inhibits ODC, an enzyme that synthesizes a polyamine required for tumor formation and growth | Intravenous |
Naxitamab-gqgk (Danyelza) | Monoclonal antibody | Neuroblastoma | Binds to GD2 on the surface of cancer cells, triggering an immune response | Intravenous |
Vincristine sulfate (Oncovin, Vincasar, Marqibo, Vincrex) | Small molecule (249332) | Neuroblastoma, AL, HL, NHL, RMS, Wilms tumor | Inhibits microtubule formation in the mitotic spindle, resulting in cell division arrest at the metaphase stage | Intravenous |
